貝達藥業(300558.SZ):股東Beta申請仲裁 要求撤銷其與公司於2013年6月簽署的《商標轉讓協議》中註冊號為3876765註冊商標的贈與
格隆匯 8 月 18日丨貝達藥業(300558.SZ)公佈,公司於近日收到了香港國際仲裁中心的通知,公司股東Beta Pharma, Inc. (“Beta”)向香港國際仲裁中心申請仲裁,要求撤銷其與公司於2013年6月簽署的《商標轉讓協議》中註冊號為3876765註冊商標的贈與。
申請人提起仲裁的《商標轉讓協議》的基礎交易事項已經履行完畢,公司合法持有並使用“3876765註冊商標”,Beta的主張毫無事實依據和法律依據。目前,前述仲裁申請尚未開庭審理,公司已組織律師團隊妥善應對,維護公司及廣大投資者的利益,後續公司將根據仲裁事項的進展情況依照法規及時公告披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.